← Back to headlines
Merck Stock Analysis Highlights KEYTRUDA Growth
An analysis suggests Merck stock appears undervalued, citing the growth of its drug KEYTRUDA and a strong pipeline as factors offsetting near-term headwinds.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
